Fmr LLC Nuvalent, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Fmr LLC holds 8,868,095 shares of NUVL stock, worth $791 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

8,868,095

Previous 8,794,857 0.83%

Holding current value

$791 Million

Previous $660 Million 1.87%

% of portfolio

0.04%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$62.76 - $81.61 $4.6 Million - $5.98 Million	73,238 Added 0.83%	8,868,095 $673 Million
Q1 2024 May 13, 2024	BUY	$72.35 - $88.99 $5.05 Million - $6.21 Million	69,787 Added 0.8%	8,794,857 $660 Million
Q4 2023 Feb 13, 2024	BUY	$42.42 - $80.28 $46.9 Million - $88.7 Million	1,105,457 Added 14.51%	8,725,070 $642 Million
Q3 2023 Nov 13, 2023	BUY	$39.12 - $49.85 $58,249 - $74,226	1,489 Added 0.02%	7,619,613 $350 Million
Q2 2023 Aug 11, 2023	SELL	$23.58 - $44.68 $1.7 Million - $3.23 Million	-72,300 Reduced 0.94%	7,618,124 $321 Million
Q1 2023 May 11, 2023	BUY	$25.42 - $33.52 $1.8 Million - $2.38 Million	70,864 Added 0.93%	7,690,424 $201 Million
Q4 2022 Feb 13, 2023	BUY	$18.46 - $36.37 $21.7 Million - $42.7 Million	1,172,889 Added 18.19%	7,619,560 $227 Million
Q3 2022 Nov 10, 2022	BUY	$13.55 - $19.92 $201,339 - $295,991	14,859 Added 0.23%	6,446,671 $125 Million
Q2 2022 Aug 12, 2022	SELL	$7.4 - $15.07 $4,255 - $8,665	-575 Reduced 0.01%	6,431,812 $87.2 Million
Q1 2022 May 13, 2022	BUY	$11.65 - $19.57 $59,182 - $99,415	5,080 Added 0.08%	6,432,387 $89.3 Million
Q3 2021 Nov 15, 2021	BUY	$18.25 - $38.35 $117 Million - $246 Million	6,427,307 New	6,427,307 $145 Million

Others Institutions Holding NUVL

# of Institutions

180

Shares Held

56.6M

Call Options Held

527K

Put Options Held

131K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.83B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account